Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Large Scale Data Solutions Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
Confirmed Presenting Companies:
Speaker Profile
M.D., Senior Physician, Kaiser Permenente
Biography
Pankaj Vij, M.D. FACP, is passionate about preventing and reversing metabolic diseases by treating their root causes. He is the Clinical Lead for Lifestyle Medicine Medical Director of Lifestyle Medicine at Kaiser Permanente. He is the Chief Architect of Crack the Wellness Code- a global community platform for health promotion that has followers world-wide. He has the author of the book Turbo Metabolism: 8 Weeks to a New You: Preventing and Reversing Diabetes, Obesity, Heart Disease, and Other Metabolic Diseases by Treating the Causes.He is a thinker, writer, and an entertaining and inspiring speaker, having delivered a TEDx talk that was viewed thousands of times.
Talk
LIFESTYLE AND LONGEVITY MEDICINE: A PERSONALIZED APPROACH TO HEALTH
Mastering the levers of health to get healthy and stay healthy. Listeners will learn how to use the data from wearables to build a road map for personal health and well-being to maximize productivity and impact.
Wellness & Aging Showcase:
Kaiser Permenente
Focused on a mission to maximize personal and community health
Speaker Profile
Ph.D., Professor and Founder, IIT Bombay
Biography
Dr. K. V. Venkatesh is a Professor in the Department of Chemical Engineering at IIT Bombay and a leading authority in systems biology, applying engineering systems principles to understand complex biological phenomena. Over three decades, his research has focused on uncovering the design principles that connect genotype to phenotype and developing dynamic physiology models of organs and diseases. His work has influenced areas such as drug discovery, wellness, and personalized healthcare.He has mentored over 40 PhD scholars, published nearly 250 papers, and is a Fellow of the National Academy of Sciences, India and is a receipient of several prestigious national awards. Building on this foundation, Dr. Venkatesh founded Metflux Research, a systems-biology-driven precision health company offering personalization and RD solutions that integrate multi-modal biology to enable predictive, preventive, and personalized healthcare. The platform is live in prominent Wellness, Neutra and Healthfood enterprises.
Talk
Precision Health Through Multi-Modal Biology for RD and Personalization
Metflux Research has built a physiology-intelligence platform that unifies multimodal datafrom genomics and microbiome to clinical markers and wearables. Population-level physiology maps advance RD in nutraceuticals, health-foods, and pharma, while explainable pathway insights enable precision-care workflows. We show how real-world implementations of physiology-centric intelligence accelerate product innovation and deliver personalized care across our client projects.
Wellness & Aging Showcase:
IIT Bombay
Metflux is a systems-biology intelligence company that unifies multi-modal data—genomics, microbiome, metabolomics, clinical markers, and wearables—to decode immuno-metabolic physiology. Its platform powers both personalized care pathways and R&D innovation for nutraceutical, health-food, wellness, and pharma partners.
Speaker Profile
Ph.D., CEO, Numiera Tx
Biography
Izi Stoll is CEO of Numiera Therapeutics and Scientific Director of the Western Institute for Advanced Study. She received bachelors degrees in Biology and Psychology from the University of Illinois at Urbana-Champaign, then earned her doctorate in Neurobiology and Behavior from the University of Washington. Dr. Stoll completed her postdoctoral research at the Wellcome Trust Centre for Mitochondrial Research, then started her own laboratory at Newcastle University, leading parallel research teams to develop new targeted therapies for cancer and lentiviral-based gene therapies for epilepsy. She has won awards for her work from the Society for Neuro Oncology and The American Federation for Aging Research. Now, as Scientific Director of the Western Institute for Advanced Study, she leads interdisciplinary teams to tackle the organizations Grand Challenges. And as CEO of Numiera Therapeutics, she is leading on the clinical development of a first-in-class target in cancer cell metabolism.
Talk
CPT1 as a novel target in oncology
With Phase I clinical data indicating improved safety over standard-of-care, and independently-replicated preclinical efficacy data from five laboratories, Numiera Therapeutics is repurposing its first-in-class CPT1 inhibitor for the treatment of glioblastoma. With orphan drug designation already in place, the company is raising a $10M equity financing round to support clinical trials and additional pipeline development.
Wellness & Aging Showcase:
Numiera Therapeutics
Numiera Therapeutics is developing small-molecule drugs for oncology indications, with a novel target in cancer cell metabolism.
